AI Article Synopsis
- Parsaclisib is a new medicine tested for patients with a type of cancer called diffuse large B-cell lymphoma in a study called CITADEL-202.
- The study included two groups: one with patients who hadn’t taken a certain type of cancer medicine before and another with patients who had.
- Although the results showed that some patients responded to parsaclisib, the study didn't meet its goals for group A, but they are still looking at how it works with other treatments.
Article Abstract
Parsaclisib, a potent, highly selective, next-generation PI3Kδ inhibitor, was evaluated as monotherapy in CITADEL-202 (NCT02998476), an open-label, multicenter, phase 2 study in patients with relapsed or refractory diffuse large B-cell lymphoma. Patients enrolled into 2 groups (A, Bruton tyrosine kinase [BTK] inhibitor naïve, = 55; B, BTK inhibitor experienced, = 5) received oral parsaclisib 20 mg once daily for 8 weeks, then 20 mg once weekly while deriving benefit. The futility boundary was crossed at the interim analysis of Group A, resulting in a negative study. Parsaclisib monotherapy demonstrated an objective response rate (ORR) of 25.5% (8 complete metabolic responses/6 partial metabolic responses) and a median duration of response of 6.2 months. ORR in Group B was 20.0% (1 complete metabolic response). Parsaclisib monotherapy demonstrated manageable toxicities with no new safety signals reported. Further evaluation of parsaclisib in combination with standard therapies and active investigational agents is underway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2020.1832660 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!